Replies to post #139806 on Biotech Values

[wallstarb]

I suspect you will see a lot of downgrades based on revenue assumptions - people were buildign in nearly $250m annual sales for apaziquone. ALTH is decent but doesnt make up for apaziquone sales loss.

I have never cared for SPPI - I thought zevelin would have been a dud - I was wrong they were able to build a company around dumpster diving for late stage compounds.

I think without apaziquone $6 - $8 is more reasonable as the latest runup was hype on apaziquone

[apljack]

SPPI did bounce off 9 ,on the face its looks decent @ 10's, the phase 3 failure counterbalanced with aquisition news on same day is weird,lol

I don't think weird, more like calculated.

The acquisition will be a long-term positive although the big question is whether sales of Fusilev will continue to show growth and at what level. Sales of Zevalin and Folytin combined are paltry, but with modest growth potential.

aj